Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

CorMedix (CRMD) EBIT Margin (2016 - 2025)

Historic EBIT Margin for CorMedix (CRMD) over the last 14 years, with Q3 2025 value amounting to 49.24%.

  • CorMedix's EBIT Margin rose 779400.0% to 49.24% in Q3 2025 from the same period last year, while for Sep 2025 it was 48.51%, marking a year-over-year increase of 4223800.0%. This contributed to the annual value of 51.43% for FY2024, which is 1428021500.0% down from last year.
  • Latest data reveals that CorMedix reported EBIT Margin of 49.24% as of Q3 2025, which was up 779400.0% from 49.18% recorded in Q2 2025.
  • CorMedix's 5-year EBIT Margin high stood at 201753.24% for Q2 2023, and its period low was 102126.07% during Q3 2022.
  • Its 5-year average for EBIT Margin is 10984.46%, with a median of 963.39% in 2024.
  • Its EBIT Margin has fluctuated over the past 5 years, first soared by 2000000000bps in 2023, then tumbled by 2000000000bps in 2024.
  • CorMedix's EBIT Margin (Quarter) stood at 13794.92% in 2021, then plummeted by -105bps to 28244.66% in 2022, then soared by 383bps to 79823.71% in 2023, then plummeted by -100bps to 41.45% in 2024, then grew by 19bps to 49.24% in 2025.
  • Its last three reported values are 49.24% in Q3 2025, 49.18% for Q2 2025, and 51.5% during Q1 2025.